The company is developing new biological entities (NBEs) focusing on antibody-drug conjugates and antibody-based therapeutics ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Sutro Biopharma (STRO – Research Report), retaining the price target of ...

Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

Equities researchers at StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a report issued on Friday. The brokerage set a “hold” rating on the ...

The rise of antibody therapeutics is transforming drug discovery, providing highly specific treatments for complex diseases ...

Researchers have created a groundbreaking antibody that combines targeting, delivery, and immune activation to treat cancer, ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...